Upgrade to SI Premium - Free Trial

FDA accepts Revolution Medicines NDA for daraxonrasib in pancreatic cancer

July 22, 2026 4:05 PM
Revolution Medicines, Inc. (Nasdaq: RVMD) announced that the U.S. Food and Drug Administration accepted for review the company's New Drug ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA